{
    "title": "112_hr6611",
    "content": "The Act may be cited as the \"Patient Access to Drugs in Shortage Act of 2012\". It includes provisions for market stability incentives. The \"Patient Access to Drugs in Shortage Act of 2012\" amends Section 1847A(b) of the Social Security Act regarding Medicare payments for sterile injectable products with 3 or fewer active manufacturers. The payment amount for these drugs is determined based on volume-weighted wholesale acquisition cost. The wholesale acquisition cost for drugs with 3 or fewer active manufacturers is determined based on volume-weighted cost. These drugs are sterile injectable products and must be multiple source drugs without exclusivity periods. The wholesale acquisition cost for sterile injectable drugs with 3 or fewer active manufacturers is determined based on volume-weighted cost, and they must be multiple source drugs without exclusivity periods. The wholesale acquisition cost for sterile injectable drugs with 3 or fewer active manufacturers is determined based on volume-weighted cost. The drug must be approved by the FDA and injected into the body. The volume-weighted average wholesale acquisition costs are calculated in a similar manner to the average sales prices, with references to wholesale acquisition cost for the drug. The HOPD prospective payment system under the Social Security Act is amended to include sterile injectable products with 3 or fewer active manufacturers. The payment for these drugs is based on volume-weighted wholesale acquisition costs from July 1, 2013, to January 1, 2020. The amendment to the HOPD prospective payment system includes sterile injectable products with 3 or fewer active manufacturers. Payment is based on volume-weighted wholesale acquisition costs from July 1, 2013, to January 1, 2020. The amendment excludes certain sterile injectable products from payment under part B of title XVIII, with guidance to be published by the Secretary by July 1, 2013. Additionally, a conforming amendment is made to section 1903(i)(10)(A) of the Social Security Act. The 340B Program under the Public Health Service Act is amended to exclude certain sterile injectable products. The amendment excludes certain sterile injectable products from payment under part B of title XVIII, with guidance to be published by the Secretary by July 1, 2013. Additionally, a study and report on the effects will be conducted by an independent entity contracted by the Secretary of Health and Human Services. The amendment excludes certain sterile injectable products from payment under part B of title XVIII, with guidance to be published by the Secretary by July 1, 2013. An independent entity will study the effects of the amendments on patient access to sterile injectable products and submit a report to Congress and the Secretary within 3 years of the enactment of the Act. SEC. 3. EXCLUSION OF BRANDED PRESCRIPTION DRUGS FROM ANNUAL FEE DURING PERIODS OF SHORTAGE. The Patient Protection and Affordable Care Act excludes branded prescription drugs from annual fees during shortages listed under the Federal Food, Drug, and Cosmetic Act. The Patient Protection and Affordable Care Act excludes branded prescription drugs from annual fees during shortages listed under the Federal Food, Drug, and Cosmetic Act. The amendment made by subsection (a) of the Act applies to sales after the date of its enactment."
}